The firm served as lead counsel on behalf of Oklahoma Medical Research Foundation in a patent infringement suit brought in the Northern District of Oklahoma against Alexion Pharmaceuticals. The patents related to complement-inhibition technology and their use in a drug marketed by Alexion to treat a rare, debilitating and life-threatening disease. After replacing OMRF’s previous counsel in the matter and soon after claim construction briefing was complete, we obtained a settlement. It included payment to our client as well as public acknowledgement that individuals affiliated with OMRF were the true inventors of the technology at issue.

Oklahoma Med. Research Found. v. Alexion Pharmaceuticals, Inc., No. 07-163 (N.D. Okla. filed Mar. 15, 2007).

Experience Center

Match our Experience to Your Needs

Experience Highlights

$375 million syndicated multicurrency revolving credit facility provided to a publicly-held contract staffing firm
Represented a lead agent and lead arranger in connection with $375 million syndicated multicurrency revolving credit facility provided to a more
Real estate acquisitions and dispositions for ING Clarion Partners
Represented investment management clients of various affiliates of  ING Clarion Partners in the acquisition and disposition of multi-family and more
Skinner Corporation
Represented Skinner Corporation, a group of furniture retailers, in their Chapter 11 cases filed in the United States Bankruptcy Court for the more
Class action for an aerospace manufacturing company
Represented an aerospace manufacturing company in a race discrimination class action lawsuit in which we defeated class certification and achieved more